Skip to main content

Table 1 Clinical trials on TAMs (from https://clinicaltrials.gov/)

From: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies

Action Agent Combination Target Status Tumor type Clinical trial number
Inhibiting the recruitment of TAMs Carlumab NA CCL2 Completed II Prostate cancer NCT00992186
CNTO 888(mAb) Gemcitabine
Paclitaxel and carboplatin
docetaxel
CCL2 Completed I Solid tumors NCT01204996
CNTO 888(mAb) NA CCL2 Completed I Solid tumors NCT00537368
PF-04136309 FOLFIRINOX* CCR2 Completed I Pancreatic neoplasms NCT01413022
MLN1202 NA CCR2 Completed II Bone metastases NCT01015560
Activating TAMs MCS110 Carboplatin and Gemcitabine CSF-1 Completed II Triple-negative breast cancer NCT02435680
MCS110 Placebo CSF-1 Completed II Cancer NCT01643850
MCS110 NA CSF-1 Terminated I/II Prostate cancer, Bone Metastases NCT00757757
IMC-CS4
(LY3022855)
NA CSF-1R Completed I Solid tumors NCT01346358
IMC-CS4 NA CSF-1R Completed I Breast or Prostate cancer NCT02265536
AMG 820 NA CSF-1R Completed I Solid tumors NCT01444404
AMG 820 pembrolizumab CSF-1R Completed I/II Pancreatic cancer, Colorectal cancer, Non-small cell lung cancer NCT02713529
Emactuzumab Atezolizumab CSF-1R
PD-L1
Completed Ib Solid tumors NCT02323191
ARRY-382 Pembrolizumab CSF-1R
PD-1
Completed I b/II Solid tumors NCT02880371
Pexidartinib Durvalumab CSF-1R
PD-L1
Completed I Pancreatic or Colorectal cancers NCT02777710
SNDX-6352 Durvalumab CSF-1R
PD-L1
Active, not recruiting I Solid tumors NCT03238027
BLZ945 PDR001 CSF-1R
PD-1
Active, not recruiting I/II Solid tumors NCT02829723
Cabiralizumab
(BMS-986227, FPA008)
Nivolumab
(BMS-936558)
CSF-1R
PD-1
Completed I Malignancies NCT03158272
Trabectedin Durvalumab (MEDI4736) PD-L1 Active, not recruiting Ib Soft-tissue sarcomas and ovarian carcinomas NCT03085225
PLX7486 NA CSF-1R Terminated I Solid tumors NCT01804530
PLX3397
(Pexidartinib)
NA CSF-1R Terminated II Glioblastoma NCT01349036
PLX3397 NA CSF-1R Completed II Hodgkin lymphoma NCT01217229
PLX3397 NA CSF-1R Terminated II Prostate cancer NCT01499043
PLX3397 Sirolimus CSF-1R Recruiting I
Recruiting II
Sarcoma
Malignant Peripheral Nerve Sheath Tumors
NCT02584647
PLX3397 Pembrolizumab CSF-1R Terminated I/II Tumors* NCT02452424
PLX3397 Eribulin CSF-1R Completed I b/II Breast cancer NCT01596751
PLX3397(Turalio) NA   Recruiting I/II Leukemias, Solid tumors NCT02390752
PLX3397
(Pexidartinib)
Paclitaxel
(Onxol)
  Completed I Solid tumors NCT01525602
Alemtuzumab NA CD52 Terminated I Ovarian/primary peritoneal cancer NCT00637390
Alemtuzumab fludarabine and cyclophosphamide CD52 Completed II Kidney cancer NCT00073879
Reprogramming TAMs Chi Lob 7/4 NA CD40 Completed I Malignancies NCT01561911
GM.CD40L* Vaccine CCL21 CD40 Completed I/II Lung cancer, Adenocarcinoma NCT01433172
CP-870,893* NA CD40 Completed I Advanced solid tumors NCT02225002
CP-870,893 Tremelimumab* CD40 Completed I Melanoma NCT01103635
CP-870,893 Paclitaxel + Carboplatin CD40 Completed I Neoplasms NCT00607048
CP-870,893 Gemcitabine CD40 Completed I Adenocarcinoma pancreas NCT01456585
RO7009789 Emactuzumab (RO5509554) CD40 Completed I Neoplasms NCT02760797
RO7009789 nab-paclitaxel, gemcitabine CD40 Completed I Pancreatic cancer NCT02588443
RO7009789 Vanucizumab, Bevacizumab CD40 Completed I Solid tumors NCT02665416
Selicrelumab (RO7009789) Atezolizumab CD40
PD-1
Completed I Solid tumors NCT02304393
APX005M Nivolumab CD40 Completed I/II Non-small cell lung cancer, Metastatic Melanoma NCT03123783
IPI-549 Nivolumab PI3K-γ
PD-1
Active, not recruiting I Solid tumors, non-small cell lung cancer, melanoma, breast cancer NCT02637531
TTI-621 PD-1/PD-L1 Inhibitor*
pegylated interferon-α2a
talimogene laherparepvec (T-Vec)
radiation
SIRPα-IgG1 Fc Terminated I Solid Tumors, Mycosis fungoides, Melanoma, Merkel-cell carcinoma, Squamous cell carcinoma, Breast carcinoma, Human papillomavirus-related malignant neoplasm, Soft tissue sarcoma NCT02890368
Hu5F9-G4 Atezolizumab CD47 Completed I Acute myeloid leukemia NCT03922477
CC-90002 NA CD47 Terminated I Leukemia, Myeloid, Acute
myelodysplastic syndromes
NCT02641002
CC-90002 Rituximab CD47 Completed I Hematologic neoplasms NCT02367196
GSK3145095 pembrolizumab RIP Terminated II Neoplasms, Pancreatic NCT03681951
NKTR-262 Bempegaldesleukin (NKTR-214)
Nivolumab
TLR7/8
PD-1
Active, not recruiting I/II Solid tumors NCT03435640
WP1066 NA STAT3 Active, not recruiting I Glioma and Brain metastasis from melanoma NCT01904123
AZD9150
(ISIS 481464)
NA STAT3 Completed I/Ib Advanced/Metastatic Hepatocellular carcinoma NCT01839604
Imprime PGG Cetuximab MAPK Completed II Colorectal Cancer NCT00912327
Immunological Adjuvant OPT-821 β-glucan   Active, not recruiting I/II Neuroblastoma NCT00911560
β-Glucan Anti-GD2 Monoclonal Antibody 3F8   Active, not recruiting I Neuroblastoma NCT00492167
  1. FOLFIRINOX*: fluorouracil, leucovorin calcium, irinotecan hydrochloride, and oxaliplatin
  2. Tumors*: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
  3. GM.CD40L*: GM-CSF-Producing and CD40L-Expressing Bystander Cell Line
  4. Tremelimumab*: Blocking Anti-CTLA-4 Antibody
  5. CP-870,893*: Agonist Anti-CD40 Antibody
  6. PD-1/PD-L1 Inhibitor*: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab